MX2021003566A - Usos terapeuticos de clusteres cuanticos atomicos. - Google Patents

Usos terapeuticos de clusteres cuanticos atomicos.

Info

Publication number
MX2021003566A
MX2021003566A MX2021003566A MX2021003566A MX2021003566A MX 2021003566 A MX2021003566 A MX 2021003566A MX 2021003566 A MX2021003566 A MX 2021003566A MX 2021003566 A MX2021003566 A MX 2021003566A MX 2021003566 A MX2021003566 A MX 2021003566A
Authority
MX
Mexico
Prior art keywords
therapeutic uses
atomic quantum
quantum clusters
aqcs
clusters
Prior art date
Application number
MX2021003566A
Other languages
English (en)
Spanish (es)
Inventor
Fernández David Buceta
Puente Fernando Domínguez
Quintela Manuel Arturo López
Original Assignee
Nanogap Sub Nm Powder S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanogap Sub Nm Powder S A filed Critical Nanogap Sub Nm Powder S A
Publication of MX2021003566A publication Critical patent/MX2021003566A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/28—Mercury; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/38—Silver; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
    • B22F1/05—Metallic powder characterised by the size or surface area of the particles
    • B22F1/054—Nanosized particles
    • C—CHEMISTRY; METALLURGY
    • C22—METALLURGY; FERROUS OR NON-FERROUS ALLOYS; TREATMENT OF ALLOYS OR NON-FERROUS METALS
    • C22C—ALLOYS
    • C22C5/00—Alloys based on noble metals
    • C22C5/06—Alloys based on silver
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C1/00—Electrolytic production, recovery or refining of metals by electrolysis of solutions
    • C25C1/12—Electrolytic production, recovery or refining of metals by electrolysis of solutions of copper
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C1/00—Electrolytic production, recovery or refining of metals by electrolysis of solutions
    • C25C1/20—Electrolytic production, recovery or refining of metals by electrolysis of solutions of noble metals
    • C—CHEMISTRY; METALLURGY
    • C25—ELECTROLYTIC OR ELECTROPHORETIC PROCESSES; APPARATUS THEREFOR
    • C25C—PROCESSES FOR THE ELECTROLYTIC PRODUCTION, RECOVERY OR REFINING OF METALS; APPARATUS THEREFOR
    • C25C5/00—Electrolytic production, recovery or refining of metal powders or porous metal masses
    • C25C5/02—Electrolytic production, recovery or refining of metal powders or porous metal masses from solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B22—CASTING; POWDER METALLURGY
    • B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
    • B22F2202/00—Treatment under specific physical conditions
    • B22F2202/11—Use of irradiation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Nanotechnology (AREA)
  • Electrochemistry (AREA)
  • Mechanical Engineering (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2021003566A 2018-09-26 2019-09-25 Usos terapeuticos de clusteres cuanticos atomicos. MX2021003566A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18196963 2018-09-26
EP18196959 2018-09-26
PCT/ES2019/070637 WO2020065115A2 (es) 2018-09-26 2019-09-25 Usos terapéuticos de clústeres cuánticos atómicos

Publications (1)

Publication Number Publication Date
MX2021003566A true MX2021003566A (es) 2021-08-16

Family

ID=68342935

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003566A MX2021003566A (es) 2018-09-26 2019-09-25 Usos terapeuticos de clusteres cuanticos atomicos.

Country Status (11)

Country Link
US (1) US20220031740A1 (enExample)
EP (1) EP3862109A2 (enExample)
JP (2) JP2022502450A (enExample)
KR (1) KR20210086606A (enExample)
CN (2) CN120053481A (enExample)
AU (2) AU2019349780B2 (enExample)
BR (1) BR112021005775A2 (enExample)
CA (1) CA3111915A1 (enExample)
IL (1) IL281663A (enExample)
MX (1) MX2021003566A (enExample)
WO (1) WO2020065115A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1303421C (zh) * 2004-03-24 2007-03-07 南京大学 一种用于有机氯、有机磷农药分析的同步净化提取方法
JP7595087B2 (ja) * 2020-05-09 2024-12-05 深▲セン▼深見医薬科技有限公司 非定型抗精神病薬による副作用の治療
CN111906328B (zh) * 2020-08-11 2022-10-25 苏州大学 一种177Lu标记的金纳米团簇及其制备方法和应用
JP2025034223A (ja) * 2023-08-30 2025-03-13 株式会社ハイレックスコーポレーション ワイヤロープ
WO2026124952A1 (fr) * 2024-12-13 2026-06-18 Saint-Gobain Glass France Substrat verrier antimicrobien

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2277531B2 (es) * 2005-08-03 2008-07-16 Universidad De Santiago De Compostela Procedimiento para la obtencion de clusteres cuanticos atomicos.
CN101113046A (zh) * 2006-07-25 2008-01-30 安正五 纳米胶体银水的制备方法
ES2319064B1 (es) * 2007-10-05 2010-02-15 Universidad De Santiago De Compostela Uso de clusteres cuanticos atomicos (aqcs) como antimicrobianos y biocidas.
CN101486733B (zh) * 2009-03-09 2011-05-25 华南师范大学 含氧桥双核钼原子簇化合物及其制备方法和用途
EP2457572A1 (en) * 2010-11-05 2012-05-30 Universidade De Santiago De Compostela Use of atomic quantum clusters (aqcs) in the prevention of cell proliferative disorders, viral infections and autoimmune diseases
WO2015015301A2 (en) * 2013-07-31 2015-02-05 Palama Ilaria El Cancer therapy with silver nanoparticles
KR102975187B1 (ko) * 2018-06-12 2026-06-08 나노갭 서브-엔엠-파우더, 쏘시에다드 아노니마 정제된 원자 양자 클러스터를 제조하는 방법

Also Published As

Publication number Publication date
BR112021005775A2 (pt) 2021-06-29
KR20210086606A (ko) 2021-07-08
WO2020065115A3 (es) 2020-05-22
CA3111915A1 (en) 2020-04-02
JP2022502450A (ja) 2022-01-11
EP3862109A2 (en) 2021-08-11
AU2025238114A1 (en) 2025-10-23
JP2024122998A (ja) 2024-09-10
AU2019349780A1 (en) 2021-03-25
CN120053481A (zh) 2025-05-30
WO2020065115A2 (es) 2020-04-02
US20220031740A1 (en) 2022-02-03
IL281663A (en) 2021-05-31
CN113179632A (zh) 2021-07-27
AU2019349780B2 (en) 2025-07-03

Similar Documents

Publication Publication Date Title
WO2020065115A3 (es) Usos terapéuticos de clústeres cuánticos atómicos
MX2025000166A (es) Un esteroide de c21-pirazolilo disustituido con 19-nor c3,3 y metodos de uso del mismo
ZA201901536B (en) Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders
MX2019005594A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia.
MX386613B (es) El uso de un péptido timosina alfa y un inhibidor de pd-1 para el tratamiento de cáncer o una metástasis de este en un sujeto.
ZA201805792B (en) Taurine and aloe synergistic anti-irritant compositions and methods
MX2017016424A (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares.
GEP20237541B (en) Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
EP4364743A3 (en) A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
MX2023010064A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y metodos de uso del mismo.
MX2020011817A (es) Metodos para tratar el linfoma.
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2021005646A (es) Métodos de tratamiento de cáncer con agentes de unión a tubulina.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
ZA202002779B (en) Dantrolene prodrugs and methods of their use
PH12018501131A1 (en) 1,3,4-thiadiazole compounds and their use in treating cancer
MX2016017403A (es) Composiciones y metodos topicos para el tratamiento de heridas.
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MX389282B (es) Composiciones y métodos para tratar sinucleinopatías.
MX2021015333A (es) Combinaciones de inhibidores para el tratamiento de enfermedades relacionadas con la expresion de dux4.
MX2021002754A (es) Tratamiento del autismo y trastornos dentro del espectro del autismo con composiciones de biotina.
WO2019075216A8 (en) Plectin-1 binding antibodies and uses thereof
MX2019012050A (es) Composicion para usar en el tratamiento de la epilepsia.
MX2019004179A (es) Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.
MY200791A (en) Composition for controlled ovarian stimulation